<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2207245622
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TAZOCIN 4.5GM VIAL + EDTA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIPERACILLIN,Tazobactam
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4,0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        92.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NUTRA MANUFACTURING INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NUTRA MANUFACTURING INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            WYETH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Piperacillin belongs to the group of medicines known as &ldquo;broad-spectrum penicillin antibiotics&rdquo;. It can kill many kinds of bacteria. Tazobactam can prevent some resistant bacteria from surviving the effects of piperacillin. This means that when piperacillin and tazobactam are given together, more types of bacteria are killed.</p><p>&nbsp;</p><p>Tazocin is used in adults and adolescents to treat bacterial infections, such as those affecting the lower respiratory tract (lungs), urinary tract (kidneys and bladder), abdomen, skin or blood. Tazocin may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to infections).</p><p>&nbsp;</p><p>Tazocin is used in children aged 2‑12 years to treat infections of the abdomen such as appendicitis, peritonitis (infection of the fluid and lining of the abdominal organs), and gallbladder (biliary) infections. Tazocin may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to infections).</p><p>&nbsp;</p><p>In certain serious infections, your doctor may consider using Tazocin in combination with other antibiotics.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use </strong><strong>Tazocin</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to piperacillin or tazobactam or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to antibiotics known as penicillins, cephalosporins or other beta‑lactamase inhibitors, as you may be allergic to Tazocin.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p><em>&nbsp;</em></p><p>Talk to your doctor, pharmacist or nurse before using Tazocin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have allergies. If you have several allergies, make sure you tell your doctor or other healthcare professional before receiving this product.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are suffering from diarrhoea before, or if you develop diarrhoea during or after your treatment. In this case, make sure you tell your doctor or other healthcare professional immediately. Do not take any medicine for the diarrhoea without first checking with your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low levels of potassium in your blood. Your doctor may want to check your kidneys before you take this medicine and may perform regular blood tests during treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney or liver problems, or are receiving haemodialysis. Your doctor may want to check your kidneys before you take this medicine, and may perform regular blood tests during treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking another antibiotic called vancomycin at the same time as Tazocin, this may increase the risk of kidney injury (see also <strong>Other medicines and Tazocin </strong>in this leaflet).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking certain medicines (called anticoagulants) to avoid an excess of blood clotting (see also <strong>Other medicines and Tazocin </strong>in this leaflet) or any unexpected bleeding occurs during the treatment. In this case, you should inform your doctor or other healthcare professional immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you develop convulsions during the treatment. In this case, you should inform your doctor or other healthcare professional.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you think you developed a new or worsening infection. In this case, you should inform your doctor or other healthcare professional.</p><p><u>&nbsp;</u></p><p>There have been reports about a disease in which the immune system makes too many of otherwise normal white blood cells called histiocytes and lymphocytes, resulting in inflammation (haemophagocytic lymphohistiocytosis). This condition may be life-threatening if not diagnosed and treated early. If you experience multiple symptoms such as fever, swollen glands, feeling weak, feeling lightheaded, shortness of breath, bruising, or skin rash, contact your doctor immediately.</p><p><u>&nbsp;</u></p><p><strong>Children </strong></p><p>&nbsp;</p><p>Piperacillin / tazobactam is not recommended for use in children below the age of 2&nbsp;years due to insufficient data on safety and effectiveness.</p><p>&nbsp;</p><p><strong>Other medicines and Tazocin</strong></p><p>&nbsp;</p><p>Tell your doctor or other healthcare professional if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. Some medicines may interact with piperacillin and tazobactam.</p><p>&nbsp;</p><p>These include:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicine for gout (probenecid). This can increase the time it takes for piperacillin and tazobactam to leave your body.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to thin your blood or to treat blood clots (e.g. heparin, warfarin or aspirin).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to relax your muscles during surgery. Tell your doctor if you are going to have a general anaesthetic.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate (medicine used to treat cancer, arthritis or psoriasis). Piperacillin and tazobactam can increase the time it takes for methotrexate to leave your body.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that reduce the level of potassium in your blood (e.g. tablets enhancing urination or some medicines for cancer).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines containing the other antibiotics tobramycin, gentamicin or vancomycin. Tell your doctor if you have kidney problems. Taking Tazocin and vancomycin at the same time may increase the risk of kidney injury even if you have no kidney problems.</p><p><em>Effect on laboratory tests</em></p><p>Tell the doctor or laboratory staff that you are taking Tazocin if you have to provide a blood or urine sample.</p><p><s>&nbsp;</s></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or other healthcare professional for advice before receiving this medicine. Your doctor will decide if Tazocin is right for you.</p><p>&nbsp;</p><p>Piperacillin and tazobactam can pass to a baby in the womb or through breast milk. If you are breast-feeding, your doctor will decide if Tazocin is right for you.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>The use of Tazocin is not expected to affect the ability to drive or use machines.</p><p><strong>&nbsp;</strong></p><p><strong>Tazocin contains sodium </strong></p><p><em>&nbsp;</em></p><p><em>Tazocin 4 g / 0.5 g </em></p><p>&nbsp;</p><p>This medicine contains 261 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 13% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>This should be taken into consideration if you are on a controlled-sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor or other healthcare professional will give you this medicine through an infusion (a drip for 30&nbsp;minutes) into one of your veins.</p><p>&nbsp;</p><p><strong>Dosage</strong></p><p>The dose of medicine given to you depends on what you are being treated for, your age, and whether or not you have kidney problems.</p><p>&nbsp;</p><p><strong>Adults and adolescents above 12&nbsp;years of age </strong></p><p>The usual dose is 4&nbsp;g / 0.5&nbsp;g of piperacillin / tazobactam given every 6‑8&nbsp;hours, which is given into one of your veins (directly into the blood stream).</p><p>&nbsp;</p><p><strong>Children aged 2 to 12&nbsp;years </strong></p><p>The usual dose for children with abdominal infections is 100&nbsp;mg / 12.5&nbsp;mg /&nbsp;kg of body weight of piperacillin&nbsp;/&nbsp;tazobactam given every 8&nbsp;hours into one of your veins (directly into the blood stream). The usual dose for children with low white blood cell counts is 80&nbsp;mg / 10&nbsp;mg /&nbsp;kg of body weight of piperacillin&nbsp;/&nbsp;tazobactam given every 6&nbsp;hours into one of your veins (directly into the blood stream).</p><p>&nbsp;</p><p>Your doctor will calculate the dose depending on your child&rsquo;s weight but each individual dose will not exceed 4&nbsp;g&nbsp;/&nbsp;0.5&nbsp;g of Tazocin.</p><p>&nbsp;</p><p>You will be given Tazocin until the sign of infection has gone completely (5 to 14&nbsp;days).</p><p><strong>&nbsp;</strong></p><p><strong>Patients with kidney problems</strong></p><p>Your doctor may need to reduce the dose of Tazocin or how often you are given it. Your doctor may also want to test your blood to make sure that your treatment is at the right dose, especially if you have to take this medicine for a long time.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>If you receive more Tazocin than you should</strong></p><p>As you will receive Tazocin from a doctor or other healthcare professional, you are unlikely to be given the wrong dose. However, if you experience side effects, such as convulsions, or think you have been given too much, tell your doctor immediately.</p><p>&nbsp;</p><p><strong>If you miss a dose of </strong><strong>Tazocin</strong></p><p>If you think you have not been given a dose of Tazocin, tell your doctor or other healthcare professional immediately.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>See a doctor immediately </strong>if you experience any of these potentially serious side effects of Tazocin:</p><p>&nbsp;</p><p><u>The serious side effects (with frequency in brackets) of Tazocin are:</u></p><p><u>&nbsp;</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious skin rashes [Stevens-Johnson syndrome, dermatitis bullous (Not known), dermatitis</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exfoliative (Not known), toxic epidermal necrolysis (Rare)] appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs include ulcers in the mouth, throat, nose, extremities, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin and potentially may be life-threatening.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe potentially fatal allergic condition (drug reaction with eosinophilia and systemic symptoms) that can involve the skin and most importantly other organs under the skin such as the kidney and the liver.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a skin condition (acute generalised exanthematous pustulosis) accompanied by fever, which consists of numerous tiny fluid filled blisters contained within large areas of swollen and reddened skin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or other parts of the body (Not known)</p><p>- &nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, wheezing or trouble breathing (Not known)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe rash or hives (Uncommon), itching or rash on the skin (Common)</p><p>- &nbsp;&nbsp;&nbsp;&nbsp; yellowing of the eyes or skin (Not known)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to blood cells [the signs include: being breathless when you do not expect it, red or brown urine (Not known), nosebleeds (Rare) and small spot bruising (Not known)], severe decrease in white blood cells (Rare)</p><p>- &nbsp;&nbsp;&nbsp;&nbsp; severe or persistent diarrhoea accompanied by a fever or weakness (Rare)&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>If any of <strong>the following </strong>side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or other healthcare professional.</p><p>&nbsp;</p><p><strong>Very common side effects</strong> (may affect more than 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&nbsp;</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yeast infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in platelets, decrease of red blood cells or blood pigment / haemoglobin, abnormal lab test (positive direct Coombs), prolonged blood clotting time (activated partial thromboplastin time prolonged)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in blood protein</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, sleeplessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain, vomiting, nausea, constipation, upset stomach</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in blood liver enzymes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal kidney blood tests</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, injection site reaction</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in white blood cells (leukopenia), prolonged blood clotting time (prothrombin time prolonged)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased blood potassium, decreased blood sugar</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (convulsions), seen in patients on high doses or with kidney problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure, inflammation of the veins (felt as tenderness or redness in the affected area), reddening of skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of a blood pigment breakdown product (bilirubin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions with redness, formation of skin lesions, nettle rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint and muscle pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (may affect up to 1 in 1,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe decrease in white blood cells (agranulocytosis), bleeding of the nose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious infection of the colon, inflammation of the mucous lining of the mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment of the top layer of the skin all over the body (toxic epidermal necrolysis)</p><p>&nbsp;</p><p><strong>Not known</strong> (cannot be estimated from the available data)<strong> side effects</strong>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe decrease of red blood cells, white blood cells and platelets (pancytopenia), decrease in white blood cells (neutropenia), decrease of red blood cells due to premature breakdown or degradation, small spot bruising, bleeding time prolonged, increase of platelets, increase of a specific type of white blood cells (eosinophilia)&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction and severe allergic reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver, yellow staining of the skin or whites of the eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious body wide allergic reaction with skin and mucous lining rashes, blistering and various skin eruptions (Stevens-Johnson Syndrome), severe allergic condition involving skin and other organs such as the kidney and the liver (drug reaction with eosinophilia and systemic symptoms),&nbsp;&nbsp; numerous tiny fluid filled blisters contained within large areas of swollen and reddened skin accompanied by fever (acute generalised exanthematous pustulosis), skin reactions with blistering (dermatitis bullous)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor kidney functions and kidney problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a form of lung disease where eosinophils (a form of white blood cell) appear in the lung in increased numbers</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute disorientation and confusion (delirium)</p><p>&nbsp;</p><p>Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.</p><p>&nbsp;</p><p>Beta-lactam antibiotics, including piperacillin tazobactam, may lead to signs of altered brain function (encephalopathy) and convulsions.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong><strong>Other</strong><strong> GCC States</strong></p><p><em>&nbsp;</em></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br /><br />Shelf life: 36 months.<br />&nbsp;</p><p>Unopened vials: Store below 30&deg;C.</p><p>&nbsp;</p><p>For single use only. Discard any unused solution.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are piperacillin and tazobactam.</p><p>Each vial contains 4&nbsp;g piperacillin (as sodium salt) and 0.5&nbsp;g tazobactam (as sodium salt).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are citric acid monohydrate, edetate disodium (EDTA) and Sodium Hydrogen Carbonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tazocin 4 g / 0.5 g is a white to off-white powder supplied in a vial.
Packs containing 1 vial.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing</strong><strong> Authorisation Holder</strong></p><p>&nbsp;</p><p>Wyeth lederle Italy</p><p><strong>&nbsp;</strong></p><p><strong>Manufactured by</strong></p><p><strong>&nbsp;</strong></p><p>Wyeth Lederle S.r.l</p><p>Via Franco Gorgone</p><p>Zona Industriale</p><p>95100 Catania</p><p>Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي بيبيراسيلين إلى مجموعة من الأدوية تُعرف باسم &quot;المضادات الحيوية واسعة المجال&quot;. فبإمكانها قتل العديد من أنواع البكتيريا. يمكن لتازوباكتام أن يمنع بعض أنواع البكتيريا المقاومة من النجاة من تأثيرات بيبيراسيلين. وهذا يعني أنه عند إعطاء بيبيراسيلين وتازوباكتام معًا، تُقتل أنواع أكثر من البكتيريا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم تازوسين في البالغين والمراهقين لعلاج العداوى البكتيرية، مثل تلك التي تُصيب السبيل التنفسي السفلي (الرئتين) أو المسالك البولية (الكليتين والمثانة) أو البطن أو الجلد أو الدم. يمكن استخدام تازوسين لعلاج العداوى البكتيرية في المرضى الذين يعانون من انخفاض تعداد خلايا الدم البيضاء (مقاومة منخفضة للعداوى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما يُستخدم تازوسين في الأطفال الذين تتراوح أعمارهم بين عامين و۱۲ عامًا لعلاج عداوى البطن مثل التهاب الزائدة الدودية والتهاب البرتوني(عدوى تصيب السائل والبطانة الداخلية للأعضاء الموجودة في منطقة البطن) وعدوى المرارة (الصفراوية. يمكن استخدام تازوسين لعلاج العداوى البكتيرية في المرضى الذين يعانون من انخفاض تعداد خلايا الدم البيضاء (مقاومة منخفضة للعداوى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في بعض حالات العداوى الخطيرة، قد ينظر طبيبك في أمر استخدام تازوسين بالتزامن مع مضادات حيوية أخرى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال تازوسين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه بيبيراسيلين أو تازوباكتام أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه المضادات الحيوية المعروفة باسم البنسلينات أو السيفالوسبورينات أو أيٍ من مثبطات البيتالاكتاماز الأخرى حيث قد تكون مصابًا بالحساسية تجاه تازوسين.</p><p dir="RTL">&nbsp;</p><p>الاحتياطات عند استعمال تازوسين</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام تازوسين:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية. إذا كنت تعاني من عدة أنواع من الحساسية، فاحرص على إخبار طبيبك أو أي من أخصائيي الرعاية الصحية الآخرين قبل تلقي هذا المنتج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الإسهال قبل، أو إذا أُصِبت بالإسهال أثناء أو بعد تلقيك للعلاج. في هذه الحالة، احرص على إخبار طبيبك أو أي من أخصائيي الرعاية الصحية الآخرين على الفور. لا تتناول أي أدوية لعلاج الإسهال دون استشارة طبيبك أولًا.</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت مستويات البوتاسيوم بدمك منخفضة. قد يرغب طبيبك في فحص كليتيك قبل تناول هذا الدواء وقد يُجري فحوصات منتظمة للدم أثناء فترة العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكلى أو الكبد، أو تخضع لغسيل الدم الكلوي. قد يرغب طبيبك في فحص كليتيك قبل تناول هذا الدواء، وقد يُجري فحوصات منتظمة للدم أثناء فترة العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مضادًا حيويًا آخر يسمى فانكوميسين في نفس الوقت مع تازوسين، فقد يزيد ذلك خطر حدوث إصابة بالكلى (انظر أيضًا قسم &quot;<strong>الأدوية الأخرى وتازوسين</strong>&quot; في هذه النشرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول بعض الأدوية (تُدعى مضادات التجلط) لتجنب تجلط الدم المفرط (انظر أيضًا قسم &quot;<strong>الأدوية الأخرى وتازوسين</strong>&quot; في هذه النشرة) أو حدوث أي نزيف غير متوقع أثناء فترة العلاج. في هذه الحالة، ينبغي عليك إخبار طبيبك أو أي من أخصائيي الرعاية الصحية الآخرين على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت بتشنجات أثناء فترة العلاج. في هذه الحالة، ينبغي عليك إخبار طبيبك أو أي من أخصائيي الرعاية الصحية الآخرين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شككت في إصابتك بعدوى جديدة أو تدهور حالة العدوى التي تعاني منها. في هذه الحالة، ينبغي عليك إخبار طبيبك أو أي من أخصائيي الرعاية الصحية الآخرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت هناك تقارير عن مرض ينتج فيه الجهاز المناعي عددًا كبيرًا جدًا من خلايا الدم البيضاء الطبيعية التي يُطلق عليها الخلايا المنسجة والخلايا الليمفاوية، مما يؤدي إلى الإصابة بالتهاب (داء البلعمة). وقد تصبح هذه الحالة مهددة للحياة إذا لم يتم تشخيصها وعلاجها في وقت مبكر.إذا كنت تعاني من أعراض عديدة مثل الحمى أو تورم الغدد أو الشعور بالضعف أو الشعور بالدوخة أو ضيق التنفس أو التكدم أو الطفح الجلدي، فاتصل بطبيبك على الفور.</p><p dir="RTL"><strong><em><u>&nbsp;</u></em></strong></p><p dir="RTL"><strong>الأطفال </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُوصى باستخدام بيبيراسيلين / تازوباكتام للأطفال أقل من عامين نظرًا لعدم وجود بيانات كافية حول الأمان والفعالية.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong><strong> </strong></p><p dir="RTL">أبلغ طبيبك أو أي من أخصائيي الرعاية الصحية الآخرين إذا كنت تتناول أو قد تلقيت مؤخرًا أو قد تتلقى أي أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية. قد تتفاعل بعض الأدوية مع بيبيراسيلين وتازوباكتام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن هذه الأدوية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج النقرس (بروبنسيد). يمكن لهذا الدواء أن يزيد من الوقت الذي يستغرقه بيبيراسيلين وتازوباكتام لمغادرة جسمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لتخفيف كثافة دمك أو لعلاج الجلطات الدموية (مثل هيبارين أو وارفارين أو أسبرين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لتهدئة عضلاتك أثناء الجراحة. أخبر طبيبك إذا كنت ستخضع لتخدير كلي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات (دواء يستخدم لعلاج السرطان أو التهاب المفاصل أو الصدفية). يمكن أن يزيد بيبيراسيلين وتازوباكتام من الوقت الذي يستغرقه ميثوتريكسات لمغادرة جسمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تخفض من مستوى البوتاسيوم بدمك (مثل الأقراص المدرّة للبول أو بعض أدوية السرطان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على المضادات الحيوية الأخرى توبراميسين، أو جنتاميسين، أو فانكوميسين. أخبر طبيبك إذا كنت تعاني من مشكلات بالكلى. قد يؤدي تناول تازوسين وفانكوميسين في نفس الوقت إلى زيادة خطر حدوث إصابة بالكلى، حتى إذا لم تكن تعاني من مشكلات في الكلى.</p><p dir="RTL"><em><u>&nbsp;</u></em></p><p><em><u>التأثير على التحاليل المعملية</u></em></p><p dir="RTL">أخبر طبيبك أو العاملين في المعمل أنك تتناول تازوسين إذا كنت ستقدم عينة دم أو بول للفحص.</p><p dir="RTL"><em><s>&nbsp;</s></em></p><p>الحمل والرضاعة</p><p dir="RTL">إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو أحد أخصائيي الرعاية الصحية الآخرين قبل تلقي هذا الدواء.</p><p dir="RTL">سيقرر طبيبكِ إذا ما كان تازوسين ملائمًا لكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يمر بيبيراسيلين وتازوباكتام إلى الطفل داخل الرحم أو من خلال لبن الثدي. إذا كنتِ ترضعين رضاعة طبيعية، فسيقرر طبيبكِ إذا ما كان تازوسين ملائمًا لكِ.</p><p dir="RTL"><em>&nbsp;</em></p><p>تأثير تازوسين على القيادة واستخدام الآلات</p><p dir="RTL">ليس من المتوقع أن يؤثر استخدام تازوسين على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL"><em>&nbsp;</em></p><p>يحتوي تازوسين على الصوديوم</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>تازوسين ٤</em> جم <strong><em>/ </em></strong><em>٥</em><em>,</em><em>۰</em><strong><em> </em></strong>جم</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">يحتوي هذا الدواء على ۲٦۱ ملجم من الصوديوم (المكون الرئيسي لملح الطهي/ملح الطعام) في كل قنينة. يعادل هذا ۱۳٪ من الحد الأقصى الموصى به من مدخول الصوديوم الغذائي اليومي لشخص بالغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي وضع هذا الأمر في الاعتبار إذا كنت تتبع نظامًا غذائيًا محدد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعطيك طبيبك أو أيٍ من أخصائيي الرعاية الصحية الآخرين هذا الدواء من خلال تسريب (تنقيط لمدة ۳۰ &nbsp;دقيقة) عبر أوردتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">تعتمد جرعة الدواء المُعطاة إليك على حالتك المرضية التي تُعالج منها وعمرك وإذا ما كنت تعاني من مشكلات بالكلى.</p><p dir="RTL">&nbsp;</p><p>البالغون والمراهقون الذين تزيد أعمارهم عن ۱۲ عامًا</p><p dir="RTL">الجرعة المعتادة هي ٤ جرام / ٥,۰<strong> </strong>جرام من بيبيراسيلين / تازوباكتام تُعطى كل ٦-۸ ساعات، يتم تلقيها عبر الأوردة (مباشرةً إلى مجرى الدم).</p><p dir="RTL">&nbsp;</p><p>الأطفال الذين تتراوح أعمارهم بين عامين إلى ۱۲ عامًا</p><p dir="RTL">تبلغ الجرعة المعتادة للأطفال المصابين بعدوى البطن ۱۰۰ ملجم / ٥,۱۲ ملجم / كلجم من وزن الجسم من بيبيراسيلين / تازوباكتام تُعطى كل ۸ ساعات عبر الأوردة (مُباشرةً إلى مجرى الدم). تبلغ الجرعة المعتادة للأطفال المصابين بتعداد منخفض لخلايا الدم البيضاء ۸۰ ملجم / ۱۰ ملجم / كلجم من وزن الجسم من بيبيراسيلين / تازوباكتام تُعطى كل ٦ ساعات عبر الأوردة (مُباشرةً إلى مجرى الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحسب طبيبك الجرعة استنادًا إلى وزن طفلك ولكن لن تتعدى كل جرعة فردية ٤ جرام / ٥,۰ جرام من تازوسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستتلقى تازوسين حتى تزول علامات العدوى بالكامل (٥ إلى ۱٤ يومًا).</p><p dir="RTL">&nbsp;</p><p>المرضى الذين يعانون من مشكلات بالكلى</p><p dir="RTL">قد يحتاج طبيبك لتقليل جرعة تازوسين أو عدد المرات التي تتلقاه فيها. قد يريد طبيبك أيضًا فحص دمك للتأكد من تلقيك العلاج بالجرعات الصحيحة، خاصةً إذا كنت مضطرًا لتناول هذا الدواء لفترة طويلة.</p><p dir="RTL"><em>&nbsp;</em></p><p>الجرعة الزائدة من تازوسين</p><p dir="RTL">نظرًا لأنك ستتلقى تازوسين من طبيب أو أخصائي رعاية صحية آخر، فإنه من غير المحتمل أن يتم إعطاؤك جرعة خاطئة. ولكن، إذا تعرضت لأي آثار جانبية، مثل التشنجات، أو كنت تعتقد بأنك قد أُعطيت جرعة عالية، فأخبر طبيبك على الفور.</p><p dir="RTL"><em>&nbsp;</em></p><p>نسيان تناول جرعة تازوسين</p><p dir="RTL">إذا كنت تعتقد بأنه قد فاتتك جرعة من تازوسين، فأخبِر طبيبك أو أيًا من أخصائيي الرعاية الصحية الآخرين على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، فاسأل طبيبك أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">وكأي دواءٍ آخر، يمكن أن يسبب هذا الدواء أثارًا جانبية، إلا أنها قد لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اذهب للطبيب على الفور</strong> إذا أُصبت بأيٍ من هذه الآثار الجانبية محتملة الخطورة لتازوسين:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تتمثل الآثار الجانبية الخطيرة (مع ذكر معدل التكرار بين قوسين) لتازوسين في:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الخطير [متلازمة ستيفنز-جونسون، التهاب الجلد الفقاعي (معدل التكرار غير معروف)، التهاب الجلد</p><p dir="RTL">التقشري (معدل التكرار غير معروف)، تقشر الأنسجة الميتة البشروية التسممي (نادر)] الذي يظهر في البداية كبقع ضاربة إلى الحُمرة تشبه دائرة التصويب أو بقع دائرية غالبًا ما توجد بثور في منتصفها تنتشر على الجذع. تتضمن العلامات الإضافية حدوث قرح في الفم والحلق والأنف والأطراف والأعضاء التناسلية والتهاب الملتحمة (عيون حمراء متورمة). قد يتطور الطفح الجلدي إلى تقرحات واسعة الانتشار أو تقشر جلدي وقد يهدد الحياة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة حساسية شديدة يُحتمل أن تكون مميتة (تفاعل دوائي مصحوب بكثرة اليوزينيات وأعراض جهازية) ويمكن أن تشمل الجلد، والأهم من ذلك أعضاء أخرى تحت الجلد مثل الكلى والكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة جلدية (البثار الطفحي المعمم الحاد) مصحوبة بحمى، تتكون من بثور عديدة صغيرة ممتلئة بالسوائل منتشرة في مناطق كبيرة من الجلد الأحمر المتورم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الشفاه أو اللسان أو أي جزء آخر من الجسم (معدل التكرار غير معروف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس أو الأزيز أو صعوبة التنفس (معدل التكرار غير معروف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الحاد، أو الشرى (غير شائع)، أو الحكة أو الطفح الجلدي على الجلد (شائع)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار العينين أو الجلد (معدل التكرار غير معروف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف خلايا الدم [تتضمن العلامات: انقطاع النفس في أوقات غير متوقعة وبول ذو لون أحمر أو بني (معدل التكرار غير معروف)، ونزيف الأنف (نادر) وكدمات على هيئة بقع صغيرة (معدل التكرار غير معروف)]، الانخفاض الشديد في عدد خلايا الدم البيضاء (نادر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الشديد أو المستمر المُصاحَب بالحمى أو الضعف (نادر)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبح أي من الآثار الجانبية <strong>التالية</strong> خطيرًا، أو إذا لاحظت أي آثار جانبية أخرى لم يرد ذكرها في هذه النشرة، فيرجى إبلاغ طبيبك أو أحد أخصائيي الرعاية الصحية الآخرين.</p><p dir="RTL">&nbsp;</p><p>الآثار الجانبية الشائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل ۱۰ أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p>&nbsp;</p><p>الآثار الجانبية الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الخميرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدموية، انخفاض عدد خلايا الدم الحمراء أو صبغة الدم / الهيموجلوبين، وجود نتائج غير طبيعية للاختبارات المعملية (نتيجة إيجابية لاختبار االكومبس المباشر)، استطالة الزمن اللازم لتخثر الدم (استطالة زمن الثرومبوبلاستين الجزئي المفعل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة البروتين في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، الأرق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن، القيء، الغثيان، الإمساك، اضطراب المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة إنزيمات الكبد في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، الحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود نتائج غير طبيعية في فحوصات الدم الخاصة بوظائف الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، تفاعلات موضع الحقن</p><p dir="RTL">&nbsp;</p><p>الآثار الجانبية غير الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم البيضاء (نقص الكريات البيضاء)، استطالة الزمن اللازم لتخثر الدم (استطالة زمن البروثرومبين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة البوتاسيوم في الدم، انخفاض نسبة السكر في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات (تشنجات)، تظهر لدى المرضى الذين يتناولون جرعات عالية أو يعانون من مشكلات في الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المنخفض، التهاب الأوردة (يتم الشعور به في صورة إيلام أو احمرار في المنطقة المصابة)، احمرار الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ناتج تحلل صبغة الدم (البيليروبين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية مصاحبة باحمرار، تكون إصابات جلدية، الطفح الجلدي القراصي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل والعضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰ شخص)<strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانخفاض الشديد في عدد خلايا الدم البيضاء (ندرة المحببات)، نزيف الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى القولون الخطيرة، التهاب البطانة المخاطية للفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال الطبقة العليا من الجلد في جميع أنحاء الجسم (تقشر الأنسجة الميتة البشروية التسممي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية ذات معدل التكرار غير المعروف</strong> (لا يمكن تقدير معدل التكرار من البيانات المتاحة)<strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانخفاض الشديد في عدد خلايا الدم الحمراء وخلايا الدم البيضاء والصفائح الدموية (قلة الكريات الشاملة)، انخفاض عدد خلايا الدم البيضاء (قلة العدلات)، انخفاض عدد خلايا الدم الحمراء نتيجة التكسر أو الانحلال المبكر، وجود كدمات على هيئة بقع صغيرة، استطالة زمن النزيف، زيادة عدد الصفائح الدموية، زيادة عدد نوع محدد من خلايا الدم البيضاء (كثرة اليوزينيات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل الحساسية وتفاعل الحساسية الشديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد، تلون الجلد أو بياض العينين باللون الأصفر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية خطير منتشر في جميع أنحاء الجسم مصحوبًا بطفح جلدي على الجلد والبطانة المخاطية، تبثر وأنواع متعددة من الطفح الجلدي (متلازمة ستيفنز جونسون)، حالة حساسية شديدة تشمل الجلد وأعضاء أخرى مثل الكلى والكبد (تفاعل دوائي مصحوب بكثرة اليوزينيات وأعراض جهازية)، ظهور العديد من البثور الصغيرة الممتلئة بالسوائل في مناطق كبيرة من الجلد الأحمر والمتورم محصوبة بالحمى (البثار الطفحي المعمم الحاد)، تفاعلات جلدية مصحوبة بتبثرات (التهاب الجلد الفقاعي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف وظائف الكلى ومشكلات الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحدى صور المرض الرئوي تظهر فيه اليوزينيات (أحد أنواع خلايا الدم البيضاء) في الرئتين بأعداد كبيرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوهان والارتباك الحاد (الهذيان)</p><p dir="RTL">ربط العلاج ببيبيراسيلين بتزايد معدل حدوث الحمى والطفح الجلدي في المرضى الذين يعانون من التليف الكيسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤدي المضادات الحيوية من فئة البيتالاكتام، بما في ذلك بيبيراسيلين تازوباكتام، إلى ظهور علامات لتغير وظائف المخ (اعتلال الدماغ) والتشنجات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير واردة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً من خلال نظام الإبلاغ القومي. بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">&middot;&nbsp;&nbsp; مركز الاتصال الموحد: ۱٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL"><em>&middot;&nbsp;&nbsp; </em>الموقع الإلكتروني: <em>https://ade.sfda.gov.sa/</em></p><p dir="RTL"><em>&nbsp;</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المدون على العلبة والقنينة بعد كلمة &quot;<strong>EXP</strong>&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.<br />&nbsp;</p><p dir="RTL">صلاحية المستحضر 36 شهر.<br />&nbsp;</p><p dir="RTL">القنينة التي لم تُفتح بعد: تُحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مُخصص للاستعمال مرة واحدة فقط. تخلص من أي محلول غير مستخدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في القمامة المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي بيبيراسيلين وتازوباكتام.</p><p dir="RTL">تحتوي كل قنينة على ٤ جرام من بيبيراسيلين (في صورة ملح صوديوم) و٥,۰ جرام من تازوباكتام (في صورة ملح صوديوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي أحادي هيدرات حمض الستريك وثنائي صوديوم الإيديتات (EDTA) وصوديوم هيدروجين كربونات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر تازوسين ٤ جرام / ٥,۰ جرام في صورة مسحوق أبيض أو أبيض مائل للصفرة يأتي في قنينة.</p><p dir="RTL">تحتوي العبوات على قنينة واحدة<strong> .</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Wyeth lederle Italy</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">Wyeth Lederle S.R.L.</p><p dir="RTL">Via Franco Gorgone Z.I</p><p dir="RTL">95100 Catania</p><p dir="RTL">&nbsp;Italy</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر ۲۰۲۱ 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tazocin 4 g / 0.5 g powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tazocin 4 g / 0.5 g powder for solution for infusion
Each vial contains piperacillin (as sodium salt) equivalent to 4 g and tazobactam (as sodium salt) equivalent to 0.5 g.
Excipient with known effect
Each vial of Tazocin 4 g / 0.5 g contains (261 mg) of sodium.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion. 

White to off-white powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tazocin is indicated for the treatment of the following infections in adults and children over 2 years of age (see sections 4.2 and 5.1):</p><p>&nbsp;</p><p><strong>Adults and adolescents</strong></p><p>&nbsp;</p><p>-&nbsp; Severe pneumonia including hospital‑acquired and ventilator‑associated pneumonia</p><p>-&nbsp; Complicated urinary tract infections (including pyelonephritis)</p><p>-&nbsp; Complicated intra‑abdominal infections</p><p>-&nbsp; Complicated skin and soft tissue infections (including diabetic foot infections)</p><p>&nbsp;</p><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>&nbsp;</p><p>Tazocin may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection.</p><p>Note: Use for bacteraemia due to extended-beta-lactamase (ESBL) producing <em>E. coli</em> and <em>K. pneumoniae</em> (ceftriaxone non-susceptible), is not recommended in adult patients, see section 5.1.</p><p>&nbsp;</p><p><strong>Children 2 to 12&nbsp;years of age</strong></p><p>&nbsp;</p><p>-&nbsp; Complicated intra-abdominal infections</p><p>&nbsp;</p><p>Tazocin may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection.</p><p><s>&nbsp;</s></p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>&nbsp;</p><p>The dose and frequency of Tazocin depends on the severity and localisation of the infection and expected&nbsp;pathogens.</p><p>&nbsp;</p><p><em>Adult and adolescent patients</em></p><p>&nbsp;</p><p><em><u>Infections</u></em></p><p>The usual dose is 4&nbsp;g&nbsp;piperacillin&nbsp;/&nbsp;0.5&nbsp;g tazobactam given every 8&nbsp;hours.</p><p>&nbsp;</p><p>For nosocomial pneumonia and bacterial infections in neutropenic patients, the recommended dose is 4&nbsp;g&nbsp;piperacillin / 0.5&nbsp;g&nbsp;tazobactam administered every 6&nbsp;hours. This regimen may also be applicable to treat patients with other indicated infections when particularly severe.</p><p>&nbsp;</p><p>The following table summarises the treatment frequency and the recommended dose for adult and adolescent patients by indication or condition:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:93%"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment frequency</strong></p></td><td style="vertical-align:top"><p><strong>Tazocin 4 g / 0.5 g</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Every 6 hours</p></td><td style="vertical-align:top"><p>Severe pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic adults with fever suspected to be due to a bacterial infection.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Every 8 hours</p></td><td style="vertical-align:top"><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra‑abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Skin and soft tissue infections (including diabetic foot infections)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>The intravenous dose should be adjusted to the degree of actual renal impairment as follows (each patient must be monitored closely for signs of substance toxicity; medicinal product dose and interval should be adjusted accordingly):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:541px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance</strong><strong> (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Tazocin</strong> <strong>(recommended dose)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 40</p></td><td style="vertical-align:top"><p>No dose adjustment necessary</p></td></tr><tr><td style="vertical-align:top"><p>20-40</p></td><td style="vertical-align:top"><p>Maximum dose suggested: 4&nbsp;g / 0.5&nbsp;g every 8&nbsp;hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>Maximum dose suggested: 4&nbsp;g / 0.5&nbsp;g every 12&nbsp;hours</p></td></tr></tbody></table><p>&nbsp;</p><p>For patients on haemodialysis, one additional dose of piperacillin / tazobactam 2&nbsp;g&nbsp;/&nbsp;0.25&nbsp;g should be administered following each dialysis period, because haemodialysis removes 30%-50% of piperacillin in 4&nbsp;hours.</p><p>&nbsp;</p><p><em>Patients with hepatic impairment</em></p><p>No dose adjustment is necessary (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 40&nbsp;ml/min.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em><em> (2-12 years of age)</em></p><p><u>&nbsp;</u></p><p><em><u>Infections</u></em></p><p>&nbsp;</p><p>The following table summarises the treatment frequency and the dose per body weight for paediatric patients 2-12 years of age by indication or condition:</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:93%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose per weight and treatment frequency</strong></p></td><td style="vertical-align:top"><p><strong>Indication / condition</strong></p></td></tr><tr><td style="vertical-align:top"><p>80&nbsp;mg Piperacillin /&nbsp;10&nbsp;mg Tazobactam per kg body weight / every 6&nbsp;hours</p></td><td style="vertical-align:top"><p>Neutropenic children with fever suspected to be due to bacterial infections*</p></td></tr><tr><td style="vertical-align:top"><p>100&nbsp;mg Piperacillin / 12.5&nbsp;mg Tazobactam per kg body weight / every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>Complicated intra-abdominal infections*</p></td></tr></tbody></table><p>* Not to exceed the maximum 4&nbsp;g / 0.5&nbsp;g per dose over 30 minutes.</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>The intravenous dose should be adjusted to the degree of actual renal impairment as follows (each patient must be monitored closely for signs of substance toxicity; medicinal product dose and interval should be adjusted accordingly):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:540px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Tazocin (recommended dose)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 50</p></td><td style="vertical-align:top"><p>No dose adjustment needed.</p></td></tr><tr><td style="vertical-align:top"><p>&pound; 50</p></td><td style="vertical-align:top"><p>70&nbsp;mg piperacillin / 8.75&nbsp;mg tazobactam / kg every 8&nbsp;hours.</p></td></tr></tbody></table><p>&nbsp;</p><p>For children on haemodialysis, one additional dose of 40&nbsp;mg&nbsp;piperacillin / 5&nbsp;mg tazobactam / kg should be administered following each dialysis period.</p><p>&nbsp;</p><p><em>Use in children aged below 2&nbsp;years</em></p><p><u>&nbsp;</u></p><p>The safety and efficacy of Tazocin in children 0- 2&nbsp;years of age has not been established.</p><p>&nbsp;</p><p>No data from controlled clinical studies are available.</p><p>&nbsp;</p><p><strong>Treatment duration</strong></p><p>&nbsp;</p><p>The usual duration of treatment for most indications is in the range of 5-14 days. However, the duration of treatment should be guided by the severity of the infection, the pathogen(s) and the patient&#39;s clinical and bacteriological progress.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p><u>&nbsp;</u></p><p>Tazocin 4&nbsp;g / 0.5&nbsp;g is administered by intravenous infusion (over 30&nbsp;minutes).</p><p>For instructions on reconstitution of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, any other penicillin antibacterial agent or to any of the excipients listed in section 6.1.

History of acute severe allergic reaction to any other beta-lactam active substances (e.g. cephalosporin, monobactam or carbapenem).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The selection of piperacillin / tazobactam to treat an individual patient should take into account the appropriateness of using a broad-spectrum semi-synthetic penicillin based on factors such as the severity of the infection and the prevalence of resistance to other suitable antibacterial agents.</p><p>&nbsp;</p><p>Before initiating therapy with Tazocin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, other beta-lactam agents (e.g. cephalosporin, monobactam or carbapenem) and other allergens. Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid [including shock]) reactions have been reported in patients receiving therapy with penicillins, including piperacillin / tazobactam. These reactions are more likely to occur in persons with a history of sensitivity to multiple allergens. Serious hypersensitivity reactions require the discontinuation of the antibiotic, and may require administration of epinephrine and other emergency measures.</p><p>&nbsp;</p><p>Tazocin may cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalised exanthematous pustulosis (see section 4.8). If patients develop a skin rash they should be monitored closely and Tazocin discontinued if lesions progress.</p><p>&nbsp;</p><p>Haemophagocytic lympohistiocytosis (HLH): Cases of HLH have been reported in patients treated with piperacillin/tazobactam, often following treatment longer than 10 days. HLH is a life-threatening syndrome of pathologic immune activation characterised by clinical signs and symptoms of an excessive systemic inflammation (e.g., fever, hepatosplenomegaly, hypertriglyceridaemia, hypofibrinogenaemia, high serum ferritin, cytopenias and haemophagocytosis). Patients who develop early manifestations of pathologic immune activation should be evaluated immediately. If diagnosis of HLH is established piperacillin/tazobactam treatment should be discontinued.</p><p>&nbsp;</p><p>Antibiotic‑induced pseudomembranous colitis may be manifested by severe, persistent diarrhoea which may be life‑threatening. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. In these cases Tazocin, should be discontinued.</p><p>&nbsp;</p><p>Therapy with Tazocin may result in the emergence of resistant organisms, which might cause super-infections.</p><p>&nbsp;</p><p>Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics. These reactions sometimes have been associated with abnormalities of coagulation tests, such as clotting time, platelet aggregation and prothrombin time, and are more likely to occur in patients with renal failure. If bleeding manifestations occur, the antibiotic should be discontinued and appropriate therapy instituted.</p><p>&nbsp;</p><p>Leukopenia and neutropenia may occur, especially during prolonged therapy; therefore, periodic assessment of haematopoietic function should be performed.</p><p>&nbsp;</p><p>As with treatment with other penicillins, neurological complications in the form of convulsions (seizures) may occur when high doses are administered, especially in patients with impaired renal function (see section 4.8).</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Tazocin 4&nbsp;g / 0.5&nbsp;g</strong></p><p>This medicinal product contains 261 mg sodium per vial, equivalent to 13% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>This should be taken into consideration for patients who are on a controlled sodium diet.</p><p>&nbsp;</p><p>Hypokalaemia may occur in patients with low potassium reserves or those receiving concomitant medicinal products that may lower potassium levels; periodic electrolyte determinations may be advisable in such patients.</p><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><p>&nbsp;</p><p>Due to its potential nephrotoxicity (see section 4.8), piperacillin/tazobactam should be used with care in patients with renal impairment or in hemodialysis patients. Intravenous dosages and administration intervals should be adjusted to the degree of renal function impairment (see section 4.2).</p><p>&nbsp;</p><p>In a secondary analysis using data from a large multicenter, randomized-controlled trial when glomerular filtration rate (GFR) was examined after administration of frequently used antibiotics in critically ill patients, the use of piperacillin/tazobactam was associated with a lower rate of reversible GFR improvement compared with the other antibiotics. This secondary analysis concluded that piperacillin/tazobactam was a cause of delayed renal recovery in these patients.</p><p>&nbsp;</p><p>Combined use of piperacillin/tazobactam and vancomycin may be associated with an increased incidence of acute kidney injury (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Non-depolarising muscle relaxants</strong></p><p>&nbsp;</p><p>Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium. Due to their similar mechanisms of action, it is expected that the neuromuscular blockade produced by any of the non-depolarising muscle relaxants could be prolonged in the presence of piperacillin.</p><p>&nbsp;</p><p><strong>Anticoagulants</strong></p><p>&nbsp;</p><p>During simultaneous administration of heparin, oral anticoagulants and other substances that may affect the blood coagulation system including thrombocyte function, appropriate coagulation tests should be performed more frequently and monitored regularly.</p><p>&nbsp;</p><p><strong>Methotrexate</strong></p><p>&nbsp;</p><p>Piperacillin may reduce the excretion of methotrexate; therefore, serum levels of methotrexate should be monitored in patients to avoid substance toxicity.</p><p><strong>&nbsp;</strong></p><p><strong>Probenecid</strong></p><p>&nbsp;</p><p>As with other penicillins, concurrent administration of probenecid and piperacillin / tazobactam produces a longer half-life and lower renal clearance for both piperacillin and tazobactam; however, peak plasma concentrations of either substances are unaffected.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Aminoglycosides </strong></p><p>&nbsp;</p><p>Piperacillin, either alone or with tazobactam, did not significantly alter the pharmacokinetics of tobramycin in subjects with normal renal function and with mild or moderate renal impairment. The pharmacokinetics of piperacillin, tazobactam, and the M1 metabolite were also not significantly altered by tobramycin administration.</p><p>The inactivation of tobramycin and gentamicin by piperacillin has been demonstrated in patients with severe renal impairment.<s> </s></p><p>&nbsp;</p><p>For information related to the administration of piperacillin / tazobactam with aminoglycosides please refer to sections 6.2 and 6.6.</p><p><strong>&nbsp;</strong></p><p><strong>Vancomycin </strong></p><p>&nbsp;</p><p>Studies have detected an increased incidence of acute kidney injury in patients concomitantly administered piperacillin/tazobactam and vancomycin as compared to vancomycin alone (see section 4.4). Some of these studies have reported that the interaction is vancomycin dose-dependent.</p><p>&nbsp;</p><p>No pharmacokinetic interactions have been noted between piperacillin / tazobactam and vancomycin.</p><p>&nbsp;</p><p><strong>Effects on laboratory tests</strong></p><p>&nbsp;</p><p>Non-enzymatic methods of measuring urinary glucose may lead to false-positive results, as with other penicillins. Therefore, enzymatic urinary glucose measurement is required under Tazocin therapy.</p><p>&nbsp;</p><p>A number of chemical urine protein measurement methods may lead to false-positive results. Protein measurement with dip sticks is not affected.</p><p>&nbsp;</p><p>The direct Coombs test may be positive.</p><p>&nbsp;</p><p>Bio-Rad Laboratories <em>Platelia Aspergillus</em> EIA tests may lead to false-positive results for patients receiving Tazocin. Cross-reactions with non-<em>Aspergillus</em> polysaccharides and polyfuranoses with Bio-Rad Laboratories <em>Platelia Aspergillus</em> EIA test have been reported.</p><p>&nbsp;</p><p>Positive test results for the assays listed above in patients receiving Tazocin should be confirmed by other diagnostic methods.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no or a limited amount of data from the use of Tazocin in pregnant women.</p><p>&nbsp;</p><p>Studies in animals have shown developmental toxicity, but no evidence of teratogenicity, at doses that are maternally toxic (see section 5.3).</p><p>&nbsp;</p><p>Piperacillin and tazobactam cross the placenta. Piperacillin / tazobactam should only be used during pregnancy if clearly indicated, i.e. only if the expected benefit outweighs the possible risks to the pregnant woman and foetus.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in human milk have not been studied. Women who are breast-feeding should be treated only if the expected benefit outweighs the possible risks to the woman and child.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>A fertility study in rats showed no effect on fertility and mating after intraperitoneal administration of tazobactam or the combination piperacillin / tazobactam (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect on the ability to drive and use machines have been performed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse reaction is diarrhoea (occurring in 1 patient out of 10).</p><p>&nbsp;</p><p>Among the most serious adverse reactions pseudo-membranous colitis and toxic epidermal necrolysis occur in 1 to 10 patients in 10,000. The frequencies for pancytopenia, anaphylactic shock and Stevens-Johnson syndrome cannot be estimated from the currently available data.</p><p>&nbsp;</p><p>In the following table, adverse reactions are listed by system organ class and MedDRA‑preferred term. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:102%"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common</p><p>(&ge;&nbsp;1/10)</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common</p><p>(&ge;&nbsp;1/100 to &lt;&nbsp;1/10)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p><p>(&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p><p>(&ge;&nbsp;1/10,000 to</p><p>&lt;&nbsp;1/1,000)</p></td><td style="vertical-align:top"><p>Frequency not known</p><p>(cannot be estimated</p><p>from available data)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>candida infection<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pseudo&shy;membranous colitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>thrombocytopenia, anaemia<sup>*</sup></p></td><td style="vertical-align:top"><p>leukopenia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>agranulocytosis</p></td><td style="vertical-align:top"><p>pancytopenia<sup>*</sup>, neutropenia, haemolytic anaemia<sup>*</sup>, thrombocytosis<sup>*</sup>, eosinophilia<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactoid shock<sup>*</sup>, anaphylactic shock<sup>*</sup>, anaphylactoid reaction<sup>*</sup>, anaphylactic reaction<sup>*</sup>, hypersensitivity<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypokalaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>delirium<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>seizure<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension, phlebitis, thrombophlebitis, flushing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>eosinophilic pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea</p></td><td style="vertical-align:top"><p>abdominal pain, vomiting, constipation, nausea, dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>stomatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatitis<sup>*</sup>, jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>rash, pruritus</p></td><td style="vertical-align:top"><p>erythema multiforme<sup>*</sup>, urticaria, rash&nbsp;maculo‑papular<sup>*</sup></p><p><sup>&nbsp;</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis<sup>*</sup></p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>*</sup>, dermatitis exfoliative, drug reaction</p><p>with eosinophilia</p><p>and systemic</p><p>symptoms</p><p>(DRESS)<sup>*</sup>, acute</p><p>generalised</p><p>exanthematous</p><p>pustulosis</p><p>(AGEP)<sup>*</sup>,<sup> </sup>dermatitis bullous, purpura</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arthralgia, myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>renal failure, tubulointerstitial nephritis<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pyrexia, injection site reaction</p></td><td style="vertical-align:top"><p>chills</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>alanine aminotransferase increased, aspartate aminotransferase increased, protein total decreased, blood albumin decreased, Coombs direct test positive, blood creatinine increased, blood alkaline phosphatase increased, blood urea increased, activated partial thromboplastin time prolonged</p></td><td style="vertical-align:top"><p>blood glucose decreased, blood bilirubin increased, prothrombin time prolonged</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>bleeding time prolonged, gamma-glutamyl transferase increased</p></td></tr></tbody></table><p>*ADR identified post marketing</p><p>&nbsp;</p><p>Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.</p><p>&nbsp;</p><p><em>Beta-lactam antibiotic class effects</em></p><p>Beta-lactam antibiotics, including piperacillin tazobactam, may lead to manifestations of encephalopathy and convulsions (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after market authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong><strong>Other</strong><strong> GCC States</strong></p><p><strong><em>&nbsp;</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>&nbsp;</p><p>There have been post-marketing reports of overdose with piperacillin / tazobactam. The majority of those events experienced, including nausea, vomiting, and diarrhoea, have also been reported with the usual recommended dose. Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).</p><p>&nbsp;</p><p><strong>Treatment</strong></p><p>&nbsp;</p><p>In the event of an overdose, piperacillin / tazobactam treatment should be discontinued. No specific antidote is known.</p><p>&nbsp;</p><p>Treatment should be supportive and symptomatic according to the patient&rsquo;s clinical presentation.</p><p>Excessive serum concentrations of either piperacillin or tazobactam may be reduced by haemodialysis (see section&nbsp;4.4).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, Combinations of penicillins incl. beta‑lactamase inhibitors; ATC code: J01C R05</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>&nbsp;</p><p>Piperacillin, a broad‑spectrum, semisynthetic penicillin exerts bactericidal activity by inhibition of both septum and cell‑wall synthesis.</p><p>&nbsp;</p><p>Tazobactam, a beta-lactam structurally related to penicillins, is an inhibitor of many beta‑lactamases, which commonly cause resistance to penicillins and cephalosporins but it does not inhibit AmpC enzymes or metallo beta-lactamases. Tazobactam extends the antibiotic spectrum of piperacillin to include many beta-lactamase‑producing bacteria that have acquired resistance to piperacillin alone.</p><p><strong>&nbsp;</strong></p><p><strong>Pharmacokinetic / Pharmacodynamic relationship</strong></p><p><u>&nbsp;</u></p><p>The time above the minimum inhibitory concentration (T&gt; MIC) is considered to be the major pharmacodynamic determinant of efficacy for piperacillin.</p><p>&nbsp;</p><p><strong>Mechanism of resistance</strong></p><p>&nbsp;</p><p>The two main mechanisms of resistance to piperacillin / tazobactam are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Inactivation of the piperacillin component by those beta‑lactamases that are not inhibited by tazobactam: beta‑lactamases in the Molecular class B, C and D. In addition, tazobactam does not provide protection against extended-spectrum beta‑lactamases (ESBLs) in the Molecular class A and D enzyme groups.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Alteration of penicillin-binding proteins (PBPs), which results in the reduction of the affinity of piperacillin for the molecular target in bacteria.</p><p>&nbsp;</p><p>Additionally, alterations in bacterial membrane permeability, as well as expression of multi‑drug efflux pumps, may cause or contribute to bacterial resistance to piperacillin&nbsp;/&nbsp;tazobactam, especially in Gram‑negative bacteria.</p><p>&nbsp;</p><p><strong>Breakpoints</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:564px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>EUCAST Clinical MIC Breakpoints for piperacillin/tazobactam (EUCAST Clinical Breakpoint Table Version 10.0, valid from 2020-01-01). For susceptibility testing purposes, the concentration of tazobactam is fixed at 4&nbsp;mg/L.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td style="vertical-align:top"><p><strong>Species-related breakpoints (S&le;/R&gt;)</strong><strong>, mg/L of piperacillin</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacterales </em>(formerly <em>Enterobacteriaceae</em>)</p></td><td style="vertical-align:top"><p>8/16</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas</em> <em>aeruginosa</em></p></td><td style="vertical-align:top"><p>&lt;0.001/16<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>species</p></td><td style="vertical-align:top"><p>-<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus </em>species<em> </em></p></td><td style="vertical-align:top"><p>-<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>Groups A, B, C, and G</p></td><td style="vertical-align:top"><p>-<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>-<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p>Viridans group streptococci</p></td><td style="vertical-align:top"><p>-<sup>6</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>0.25/0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis </em></p></td><td style="vertical-align:top"><p>-<sup>7</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gram-positive anaerobes (except<em> Clostridioides difficile</em>)</p></td><td style="vertical-align:top"><p>8/16</p></td></tr><tr><td style="vertical-align:top"><p>Gram-negative anaerobes</p></td><td style="vertical-align:top"><p>8/16</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related (PK/PD) breakpoints</p></td><td style="vertical-align:top"><p>4/16</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup> For several agents, EUCAST has introduced breakpoints which categorise wild-type organisms (organisms without phenotypically detectable acquired resistance mechanisms to the agent) as &quot;Susceptible, increased exposure (I)&quot; instead of &quot;Susceptible, standard dosing regimen (S)&quot;. Susceptible breakpoints for these organism‑agent combinations are listed as arbitrary, &quot;off scale&quot; breakpoints of S&nbsp;&le;&nbsp;0.001&nbsp;mg/L.</p><p><sup>2</sup> Most staphylococci are penicillinase producers, and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to &beta;-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. Ampicillin susceptible <em>S. saprophyticus</em> are <em>mecA</em>-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).</p><p><sup>3 </sup>Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in <em>E. faecalis</em> (confirm with MIC) but common in <em>E.&nbsp;faecium</em>.</p><p><sup>4</sup> The susceptibility of <em>Streptococcus</em> groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for <em>Streptococcus</em> group B. <em>Streptococcus</em> groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.</p><p><sup>5 </sup>The oxacillin 1 &micro;g disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone &ge;20 mm, or benzylpenicillin MIC &le;0.06&nbsp;mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with &ldquo;Note&rdquo; can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as &ldquo;susceptible, increased exposure&rdquo; (I). <em>Streptococcus pneumoniae</em> do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. Susceptibility inferred from ampicillin (MIC or zone diameter).</p><p><sup>6 </sup>For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.</p><p><sup>7</sup> Susceptibility can be inferred from amoxicillin-clavulanic acid.</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Susceptibility</strong></p><p>&nbsp;</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:567px"><thead><tr><td style="vertical-align:top"><p><strong>Groupings of relevant species according to piperacillin / tazobactam susceptibility</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>COMMONLY SUSCEPTIBLE SPECIES</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus faecalis</em><em> (ampicillin- or penicillin-susceptible isolates only)</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Listeria monocytogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Staphylococcus aureus</em><em> </em>(methicillin-susceptible isolates only)</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Staphylococcus </em>species<em>, coagulase negative</em> (methicillin-susceptible isolates only)</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Streptococcus agalactiae </em>(Group B streptococci)<sup>&dagger;</sup></p><p><em>Streptococcus pyogenes </em><em>&nbsp;</em>(Group A streptococci)<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Citrobacter koseri</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemophilus influenzae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Proteus mirabilis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic Gram-positive micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clostridium </em>species</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eubacterium </em>species</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Anaerobic gram-positive cocci<sup>&dagger;&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic Gram-negative micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacteroides fragilis </em>group</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fusobacterium </em>species</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Porphyromonas </em>species</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevotella </em>species</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:567px"><thead><tr><td style="vertical-align:top"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Enterococcus faecium</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Streptococcus pneumoniae</em><sup>&dagger;</sup><em> </em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Streptococcus viridans group</em><sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Acinetobacter baumannii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Citrobacter freundii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enterobacter </em>species</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Escherichia coli</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Klebsiella pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Morganella morganii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proteus vulgaris</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Providencia ssp.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serratia </em>species</p></td></tr><tr><td style="vertical-align:top"><p><strong>INHERENTLY RESISTANT ORGANISMS</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Corynebacterium jeikeium</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Burkholderia cepacia</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Legionella </em>species</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Ochrobactrum </em><em>anthropi</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chlamydophila pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mycoplasma pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><sup>&dagger; </sup>Streptococci are not &beta;-lactamase producing bacteria; resistance in these organisms is due to alterations in penicillin-binding proteins (PBPs) and, therefore, susceptible isolates are susceptible to piperacillin alone. Penicillin resistance has not been reported in <em>S. pyogenes</em>.</p><p><sup>&dagger;&dagger; </sup>Including <em>Anaerococcus</em>, <em>Finegoldia</em>, <em>Parvimonas</em>, <em>Peptoniphilus</em>, and <em>Peptostreptococcus</em> spp<u>.</u></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Merino Trial (blood stream infections due to ESBL producers)</strong></p><p>&nbsp;</p><p>In a prospective, non-inferiority, parallel-group, published randomized clinical trial, definitive (i.e. based on susceptibility confirmed <em>in-vitro</em>) treatment with piperacillin/tazobactam, compared with meropenem, did not result in a non-inferior 30-day mortality in adult patients with ceftriaxone-non-susceptible <em>E.&nbsp;coli</em> or <em>K.&nbsp;pneumoniae</em> blood stream infections.</p><p>&nbsp;</p><p>A total of 23 of 187 patients (12.3%) randomized to piperacillin/tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6% [1‑sided 97.5% CI &minus; &infin; to 14.5%]; P = 0.90 for non-inferiority). The difference did not meet the non‑inferiority margin of 5%.</p><p>&nbsp;</p><p>Effects were consistent in an analysis of the per-protocol population, with 18 of 170 patients (10.6%) meeting the primary outcome in a piperacillin/tazobactam group compared with 7 of 186 (3.8%) in the meropenem group (risk difference, 6.8% [one-sided 97.5% CI, - &infin; to 12.8%]; P = 0.76 for non‑inferiority).</p><p>&nbsp;</p><p>Clinical and microbiological resolution (secondary outcomes) by day 4 occurred in 121 of 177 patients (68.4%) in the piperacillin/tazobactam group compared with 138 of 185 (74.6%), randomized to meropenem (risk difference, 6.2% [95% CI &minus; 15.5 to 3.1%]; P = 0.19). For secondary outcomes, statistical tests were 2-sided, with a P &lt;0.05 considered significant.</p><p>&nbsp;</p><p>In this trial, a mortality imbalance between study groups was found. It was supposed that deaths occurred in piperacillin/tazobactam group were related to underlying diseases rather than to the concomitant infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>&nbsp;</p><p>The peak piperacillin and tazobactam concentrations after 4&nbsp;g&nbsp;/&nbsp;0.5&nbsp;g administered over 30&nbsp;minutes by intravenous infusion are 298&nbsp;&micro;g/ml and 34&nbsp;&micro;g/ml respectively.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>&nbsp;</p><p>Both piperacillin and tazobactam are approximately 30% bound to plasma proteins. The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound. Protein binding of the tazobactam metabolite is negligible.</p><p>&nbsp;</p><p>Piperacillin / tazobactam is widely distributed in tissues and body fluids including intestinal mucosa, gallbladder, lung, bile, and bone.<strong><sup> </sup></strong>Mean tissue concentrations are generally 50&nbsp;to&nbsp;100% of those in plasma. Distribution into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins.</p><p>&nbsp;</p><p><strong>Biotransformation</strong></p><p>&nbsp;</p><p>Piperacillin is metabolised to a minor microbiologically active desethyl metabolite. Tazobactam is metabolised to a single metabolite that has been found to be microbiologically inactive.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p>&nbsp;</p><p>Piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion.</p><p>&nbsp;</p><p>Piperacillin is excreted rapidly as unchanged substance, with 68% of the administered dose appearing in the urine. Tazobactam and its metabolite are eliminated primarily by renal excretion, with 80% of the administered dose appearing as unchanged substance and the remainder as the single metabolite. Piperacillin, tazobactam, and desethyl piperacillin are also secreted into the bile.</p><p>&nbsp;</p><p>Following single or multiple doses of piperacillin / tazobactam to healthy subjects, the plasma half‑life of piperacillin and tazobactam ranged from 0.7&nbsp;to&nbsp;1.2&nbsp;hours and was unaffected by dose or duration of infusion. The elimination half‑lives of both piperacillin and tazobactam are increased with decreasing renal clearance.</p><p>&nbsp;</p><p>There are no significant changes in piperacillin pharmacokinetics due to tazobactam. Piperacillin appears to slightly reduce the clearance of tazobactam.</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p>&nbsp;</p><p>The half-life of piperacillin and of tazobactam increases by approximately 25% and 18%, respectively, in patients with hepatic cirrhosis compared to healthy subjects.</p><p>&nbsp;</p><p>The half-life of piperacillin and tazobactam increases with decreasing creatinine clearance. The increase in half-life is two‑fold and four‑fold for piperacillin and tazobactam, respectively, at creatinine clearance below 20&nbsp;ml/min compared to patients with normal renal function.</p><p>&nbsp;</p><p>Haemodialysis removes 30%&nbsp;to&nbsp;50% of piperacillin / tazobactam, with an additional 5% of the tazobactam dose removed as the tazobactam metabolite. Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 18% of the tazobactam dose removed as the tazobactam metabolite.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In a population PK analysis, estimated clearance for 9&nbsp;month‑old to 12&nbsp;year‑old patients was comparable to adults, with a population mean (SE) value of 5.64&nbsp;(0.34)&nbsp;ml/min/kg. The piperacillin clearance estimate is 80% of this value for paediatric patients 2‑9&nbsp;months of age. The population mean (SE) for piperacillin volume of distribution is 0.243&nbsp;(0.011)&nbsp;l/kg and is independent of age.</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>The mean half-life for piperacillin and tazobactam were 32% and 55% longer, respectively, in the elderly compared with younger subjects. This difference may be due to age-related changes in creatinine clearance.</p><p>&nbsp;</p><p><em>Race</em></p><p>No difference in piperacillin or tazobactam pharmacokinetics was observed between Asian (n=9) and Caucasian (n=9) healthy volunteers who received single 4&nbsp;g&nbsp;/&nbsp;0.5&nbsp;g&nbsp;doses.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity and genotoxicity. Carcinogenicity studies have not been conducted with piperacillin&nbsp;/&nbsp;tazobactam.</p><p>&nbsp;</p><p>A fertility and general reproduction study in rats using intraperitoneal administration of tazobactam or the combination piperacillin&nbsp;/&nbsp;tazobactam reported a decrease in litter size and an increase in fetuses with ossification delays and variations of ribs, concurrent with maternal toxicity. Fertility of the F1 generation and embryonic development of F2 generation were not impaired.</p><p>&nbsp;</p><p>Teratogenicity studies using intravenous administration of tazobactam or the combination piperacillin&nbsp;/&nbsp;tazobactam in mice and rats resulted in slight reductions in rat fetal weights at maternally toxic doses but did not show teratogenic effects.</p><p>&nbsp;</p><p>Peri/postnatal development was impaired (reduced pup weights, increase in stillbirths, increase in pup mortality) concurrent with maternal toxicity after intraperitoneal administration of tazobactam or the combination piperacillin / tazobactam in the rat.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Edetate disodium (EDTA)</p><p>Citric acid monohydrate<br />Sodium Hydrogen Carbonate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section&nbsp;6.6.</p><p>&nbsp;</p><p>Whenever Tazocin is used concurrently with another antibiotic (e.g. aminoglycosides), the substances must be administered separately. The mixing of beta-lactam antibiotics with an aminoglycoside <em>in vitro</em> can result in substantial inactivation of the aminoglycoside.</p><p>&nbsp;</p><p>Tazocin should not be mixed with other substances in a syringe or infusion bottle since compatibility has not been established.</p><p>&nbsp;</p><p>Due to chemical instability, Tazocin should not be used in solutions containing only sodium bicarbonate.</p><p>&nbsp;</p><p>Tazocin should not be added to blood products or albumin hydrolysates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Tazocin after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month
Unopened vial: 36 months

Reconstituted solution in vial

Chemical and physical in-use stability has been demonstrated for up to 24 hours when stored at 25 C and 48 hours when stored in a refrigerator at 2-8°C, when reconstituted with one of the compatible solvents for reconstitution (see section 6.6).

Diluted reconstituted solution, for infusion

The diluted reconstituted solution when using one of the compatible solvents at the suggested dilution volume (see section 6.6), demonstrated chemical and physical in-use stability for up to 24 hours when stored at 25 C and 48 hours when stored in a refrigerator at 2-8°C.

From a microbiological point of view, the reconstituted and diluted solutions should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 25 C and 48 hours at 2-8°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unopened vials: Store below 30&deg;C.</p><p>&nbsp;</p><p>For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tazocin 4&nbsp;g / 0.5&nbsp;g powder for solution for infusion:</p><p>Type I glass vial with a butyl rubber stopper and flip‑off seal.</p><p>Pack sizes: 1 vial per carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of reach of children.</p><p>&nbsp;</p><p>The reconstitution and dilution is to be made under aseptic conditions. The solution is to be inspected visually for particulate matter and discolouration prior to administration. The solution should only be used if the solution is clear and free from particles.</p><p><strong>&nbsp;</strong></p><p><strong>Intravenous use</strong></p><p>&nbsp;</p><p>Reconstitute each vial with the volume of solvent shown in the table below, using one of the compatible solvents for reconstitution.<sup> </sup>Swirl until dissolved. When swirled constantly, reconstitution generally occurs within 5 to 10&nbsp;minutes (for details on handling, please see below).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:561px"><tbody><tr><td style="vertical-align:top"><p><strong>Content of vial </strong></p></td><td style="vertical-align:top"><p><strong>Volume of solvent* to be added to vial</strong></p></td></tr><tr><td style="vertical-align:top"><p>4&nbsp;g / 0.5 g (4&nbsp;g piperacillin and 0.5&nbsp;g tazobactam)</p></td><td style="vertical-align:top"><p>20&nbsp;ml</p></td></tr></tbody></table><p>&nbsp;</p><p><u>* Compatible solvents for reconstitution:</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.9% (9&nbsp;mg/ml) sodium chloride solution for injection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sterile water for injections<sup>(1)</sup></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucose 5%</p><p><sup>&nbsp;</sup></p><p><sup>(1)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maximum recommended volume of sterile water for injection per dose is 50&nbsp;ml.</p><p>&nbsp;</p><p>The reconstituted solutions should be withdrawn from the vial by syringe. When reconstituted as directed, the vial contents withdrawn by syringe will provide the labelled amount of piperacillin and tazobactam.</p><p>&nbsp;</p><p><u>The reconstituted solutions may be further diluted to the desired volume (e.g. 50&nbsp;ml to 150&nbsp;ml) with one of the following compatible solvents:</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.9% (9&nbsp;mg/ml) sodium chloride solution for injection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucose 5%</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dextran 6% in 0.9% (9 mg/ml) sodium chloride</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactated Ringers injection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hartmann&rsquo;s solution</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringer&rsquo;s acetate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringer&rsquo;s acetate/malate</p><p>&nbsp;</p><p><strong>Co-administration with aminoglycosides</strong></p><p>&nbsp;</p><p>Due to the <em>in vitro</em> inactivation of the aminoglycoside by beta-lactam antibiotics, Tazocin and the aminoglycoside are recommended for separate administration. Tazocin and the aminoglycoside should be reconstituted and diluted separately when concomitant therapy with aminoglycosides is indicated.</p><p>&nbsp;</p><p>In circumstances where co-administration is recommended, Tazocin is compatible for simultaneous co-administration via Y-site infusion only with the following aminoglycosides under the following conditions:</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td><p><strong>Aminoglycoside</strong></p></td><td><p><strong>Tazocin Dose</strong></p></td><td><p><strong>Tazocin</strong> <strong>diluent volume (ml)</strong></p></td><td><p><strong>Aminoglycoside</strong></p><p><strong>concentration range* (mg/ml)</strong></p></td><td><p><strong>Acceptable diluents</strong></p></td></tr><tr><td><p>Amikacin</p></td><td><p>4 g / 0.5 g</p></td><td><p>50, 100, 150</p></td><td><p>1.75 &ndash; 7.5</p></td><td><p>0.9% sodium chloride or<br />5% glucose</p></td></tr><tr><td><p>Gentamicin</p></td><td><p>4 g / 0.5 g</p></td><td><p>50, 100, 150</p></td><td><p>0.7 &ndash; 3.32</p></td><td><p>0.9% sodium chloride or<br />5% glucose</p></td></tr></tbody></table><p>* The dose of aminoglycoside should be based on patient weight, status of infection (serious or life‑threatening) and renal function (creatinine clearance).</p><p>&nbsp;</p><p>Compatibility of Tazocin with other aminoglycosides has not been established. Only the concentration and diluents for amikacin and gentamicin with the dose of Tazocin listed in the above table have been established as compatible for co‑administration via Y‑site infusion. Simultaneous co-administration via Y‑site in any manner other than listed above may result in inactivation of the aminoglycoside by Tazocin.</p><p>&nbsp;</p><p>See section 6.2 for incompatibilities.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><u>&nbsp;</u></p><p>For single use only. Discard any unused solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Wyeth lederle Italy 

MANUFACTURED BY
Wyeth Lederle S.r.l
Via Franco Gorgone
Zona Industriale
95100 Catania
Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>